Hair Relaxer Lawsuit: Cancer Claims

Chemical hair relaxers — including products sold by L'Oreal, Revlon, and other major brands — have been linked to uterine cancer and ovarian cancer in peer-reviewed research. Thousands of women have filed hair relaxer lawsuits seeking compensation, and federal litigation is now centralized in a multidistrict proceeding in Chicago.

What Is the Hair Relaxer Lawsuit?

The hair relaxer lawsuit is a growing wave of personal injury claims against manufacturers of chemical hair straightening products, alleging that long-term use caused uterine cancer, ovarian cancer, and other serious reproductive conditions. Plaintiffs argue that companies like L'Oreal and Revlon knew or should have known their products contained endocrine-disrupting chemicals and failed to warn consumers. These claims are consolidated as mass torts, not a class action, meaning each woman's case is treated individually based on her own injuries and history.

The litigation is centralized in the U.S. District Court for the Northern District of Illinois under MDL No. 3060, overseen by Judge Mary Rowland. As of mid-2026, more than 8,500 cases have been filed in the MDL — one of the fastest-growing product liability dockets in the country.

The core legal theory is straightforward: manufacturers sold a product that contained hazardous chemicals, marketed it aggressively to Black women, and never disclosed the documented health risks.

The Science Linking Relaxers to Cancer

A landmark 2022 study published in the Journal of the National Cancer Institute found that women who used chemical hair straighteners frequently were more than twice as likely to develop uterine cancer compared to women who never used them. Researchers from the National Institutes of Health (NIH) analyzed data from more than 33,000 women enrolled in the Sister Study, a long-running federal research cohort. Women who reported using hair relaxers four or more times per year in the past 12 months had a 2.55 times greater risk of uterine cancer.

The mechanism is chemical exposure. Hair relaxers often contain endocrine-disrupting compounds (EDCs) — chemicals that interfere with the body's hormone system. Key culprits identified in testing include parabens, formaldehyde and formaldehyde-releasing compounds, bisphenol A (BPA), and cyclosiloxanes. These chemicals are absorbed through the scalp, especially when the product is applied near or at the scalp, which is typical for relaxer use.

A separate 2022 study in Carcinogenesis found a statistically significant association between hair relaxer use and ovarian cancer risk, adding to the body of evidence that EDC exposure from these products affects the reproductive system broadly.

Why Black Women Bear a Disproportionate Burden

Research consistently shows that Black women use chemical hair relaxers at higher rates than other demographic groups, often starting in childhood. The NIH Sister Study data showed that approximately 60% of Black women in the cohort reported using hair straighteners, compared to about 10% of non-Hispanic white women. This disparity means the health burden of these products falls disproportionately on one community — a fact that plaintiff attorneys and public health advocates have highlighted in filings and public statements.

Which Brands Are Named?

Multiple major cosmetics manufacturers have been named as defendants in hair relaxer cancer lawsuits. The most prominent defendant is L'Oreal USA, whose brands include Dark and Lovely, Soft Sheen-Carson, and Mizani. Other defendants include Revlon (which filed for bankruptcy in 2022 but whose successor entities remain in litigation), Strength of Nature (makers of African Pride and Motions brands), and Namaste Laboratories (Just for Me brand).

The L'Oreal hair relaxer lawsuit draws the most attention because L'Oreal holds the largest market share in this product category and has the deepest pockets. Plaintiffs allege L'Oreal's internal documents show awareness of EDC risks that the company chose not to disclose to consumers.

Conditions That May Qualify

Uterine cancer (also called endometrial cancer) is the primary qualifying condition in the hair relaxer litigation. The NIH study's specific finding about a 2.55x elevated risk for frequent users is the scientific anchor for most claims. However, attorneys and courts are also evaluating claims related to ovarian cancer, uterine fibroids (non-cancerous but debilitating), and endometriosis.

Uterine Cancer

Uterine cancer is the most common gynecologic cancer in the United States, with the American Cancer Society estimating about 67,880 new cases per year. It arises in the lining of the uterus (endometrium) and is strongly influenced by estrogen exposure — which is why endocrine-disrupting chemicals are a plausible causal mechanism. Most lawsuits require a formal uterine cancer diagnosis (not just a suspicion) to qualify.

Ovarian Cancer

Ovarian cancer claims are supported by the Carcinogenesis study data. Ovarian cancer is harder to detect early and has a lower survival rate than uterine cancer, which courts may factor into damages calculations. Attorneys are actively accepting ovarian cancer cases, though the scientific evidence is currently considered somewhat less robust than the uterine cancer data.

Uterine Fibroids and Endometriosis

Some firms are also evaluating fibroids and endometriosis claims based on separate epidemiological research. These cases are generally considered lower-tier and may face a higher evidentiary bar. Consult an attorney to assess whether your specific diagnosis is currently being accepted in the MDL.

Who May Be Eligible to File

Women who used chemical hair relaxers regularly for several years and later developed uterine cancer, ovarian cancer, or certain other reproductive conditions may be eligible to file a hair relaxer lawsuit. Most attorneys are currently screening for plaintiffs who meet three core criteria: regular use of a qualifying product, a diagnosis of uterine or ovarian cancer, and a diagnosis that occurred after a period of consistent product use.

Specific eligibility factors attorneys typically evaluate include:

• Product use: Used a chemical hair relaxer (lye or no-lye formula) at least four times per year for a minimum of one year, or had consistent use over several years.
• Diagnosis: Received a confirmed diagnosis of uterine cancer or ovarian cancer (pathology report preferred).
• Timing: Diagnosis occurred after a period of documented or recalled product use.
• Statute of limitations: The claim is within your state's deadline to file — typically two to four years from diagnosis or discovery of the link.

This litigation is handled as a mass tort, not a class action. That distinction matters: each plaintiff's case is evaluated on its own merits, and your potential recovery depends on your individual damages, not a shared pool. Check your eligibility to see whether your history and diagnosis align with current intake criteria.

Mass Tort vs. Class Action: What Is the Difference?

In a mass tort, thousands of plaintiffs file individual lawsuits that are coordinated for efficiency, but each person retains a separate claim and can receive a different damages amount based on their unique injuries. In a class action, one group of plaintiffs sues together, and all members share in a single pool of damages. Hair relaxer cases are being handled as defective product claims under the mass tort framework because each woman's medical history, cancer severity, treatment costs, and losses are different.

For cancer diagnoses — which involve surgery, chemotherapy, lost income, and profound personal suffering — the mass tort structure typically delivers better individual outcomes than a class action would.

What Damages Can Be Recovered?

Damages in hair relaxer cancer lawsuits fall into two main categories: economic damages and non-economic damages. Economic damages cover measurable financial losses. Non-economic damages compensate for pain, suffering, and loss of quality of life.

Economic Damages

Economic damages include past and future medical expenses (surgery, chemotherapy, radiation, follow-up care), lost wages and loss of earning capacity, and out-of-pocket costs like travel for treatment and home care assistance. For a uterine cancer diagnosis requiring a hysterectomy and chemotherapy, these costs can easily exceed $100,000 to $300,000 depending on the treatment protocol and recovery path.

Non-Economic Damages

Non-economic damages include compensation for physical pain, emotional distress, loss of fertility (a major element for women who had hysterectomies before completing their families), and loss of enjoyment of life. These damages vary widely by plaintiff and are one reason mass tort awards differ so significantly from person to person.

Punitive Damages

In cases where plaintiffs can show a defendant knew about risks and concealed them, courts may award punitive damages on top of compensatory damages. Punitive damages are intended to punish especially reckless or malicious conduct and deter future misconduct. Whether punitive damages will be available in the hair relaxer MDL will depend on what internal documents are produced during discovery.

The MDL Timeline

MDL 3060, In re: Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation, was established in February 2023 by the U.S. Judicial Panel on Multidistrict Litigation. The case is before the U.S. District Court for the Northern District of Illinois in Chicago. Key phases in federal MDL litigation include:

• Centralization: Cases from across the country were consolidated into one court for coordinated pretrial proceedings. (Complete — February 2023.)
• Discovery: Plaintiffs' attorneys and defense lawyers exchange documents, depose corporate witnesses, and retain expert scientists. (Ongoing through 2025–2026.)
• Bellwether trials: A handful of representative cases will be tried before a jury to test legal theories and help both sides gauge the value of claims. (Expected late 2026 to 2027.)
• Settlement or trial: Most MDLs resolve through a global settlement after bellwether verdicts set a price benchmark. Trials for remaining plaintiffs may follow.

The U.S. Courts website explains how MDL proceedings work in detail. The National Cancer Institute maintains a fact sheet on hair dye and chemical straightener risks that is updated as new research emerges.

One non-obvious detail: because Revlon filed for bankruptcy in mid-2022 — just months before the NIH study was published — plaintiffs with Revlon-branded products may need to pursue recovery through the bankruptcy estate or against successor entities, which involves a different legal process from the main MDL. An attorney experienced in this litigation will know how to navigate that complexity.

How to Check Your Eligibility

The fastest way to find out whether you may have a hair relaxer lawsuit claim is to complete an eligibility screening. You will typically need to provide your history of chemical hair relaxer use (which brands, how often, for how long), your cancer diagnosis and approximate date, and any medical documentation you have available. You do not need to have all records in hand to start the process.

Most plaintiff firms handling these cases work on a contingency fee basis, which means you pay nothing upfront and the attorney only collects a fee if you recover compensation. The standard contingency fee in mass tort cases ranges from 33% to 40% of the recovery, though this varies by firm and jurisdiction.

Statutes of limitations are a serious concern. Most states give you two to four years from diagnosis — or from when you reasonably could have known your cancer was linked to a product — to file a claim. Waiting too long can permanently bar your case. If you were diagnosed with uterine or ovarian cancer and used hair relaxers regularly, you should speak with an attorney as soon as possible to preserve your rights.

Check your eligibility now using our free screening tool to see whether your situation aligns with current case intake criteria.

Frequently Asked Questions

What brands of hair relaxers are included in the lawsuit?

L'Oreal-owned brands (Dark and Lovely, Soft Sheen-Carson, Mizani), Revlon, African Pride, Motions, Just for Me, and ORS Olive Oil are among the brands named. The key factor is whether the product is a chemical hair relaxer — lye-based (sodium hydroxide) or no-lye (guanidine or calcium hydroxide) — not a specific brand, though attorneys may prioritize certain brands based on available scientific testing data.

Do I have to have uterine cancer to file a hair relaxer lawsuit?

Uterine cancer is the primary qualifying condition with the strongest scientific support. Ovarian cancer claims are also being accepted by many firms. Conditions like uterine fibroids and endometriosis are evaluated on a case-by-case basis, but the eligibility bar is generally higher for non-cancer diagnoses. Speak to a mass tort attorney for a current assessment of which diagnoses are being accepted.

How long do hair relaxer lawsuits take to resolve?

Mass tort MDL cases typically take three to six years from consolidation to widespread resolution. MDL 3060 was established in early 2023, and bellwether trials are anticipated in 2026 to 2027. A broad settlement could come after those results — possibly 2027 to 2028 — though that timeline is not guaranteed. Individual cases that settle early or go to trial first may resolve sooner.

How much money can I recover from a hair relaxer lawsuit?

No attorney can ethically guarantee a specific outcome, and no settlements have been publicly announced in this MDL as of mid-2026. Potential recovery depends on your diagnosis severity, treatment costs, lost income, and pain and suffering. For cancer diagnoses requiring major surgery and chemotherapy, settlements in comparable product liability cases have ranged from hundreds of thousands to several million dollars per plaintiff. Actual results vary significantly.

I used a hair relaxer but I was never diagnosed with cancer. Can I still file?

Most active lawsuits require a cancer diagnosis. Medical monitoring claims — where plaintiffs seek funding for ongoing cancer surveillance — have been raised in some filings, but courts have not uniformly accepted them in this litigation. If you used relaxers regularly and have concerns, discuss screening options with your physician and check back as the litigation develops.

What is the statute of limitations for a hair relaxer lawsuit?

Statutes of limitations vary by state, typically ranging from two to four years from the date of diagnosis or the date you discovered (or reasonably should have discovered) the link between the product and your condition. The "discovery rule" may extend your deadline if the connection was not publicly known when you were diagnosed. Do not rely on a general answer — consult an attorney promptly to understand the exact deadline in your state.

Is the hair relaxer lawsuit a class action?

No. The hair relaxer litigation is a mass tort consolidated into a multidistrict litigation (MDL), not a class action. Each plaintiff maintains an individual claim, retains her own attorney, and may receive a damages amount specific to her own medical history and losses. You must actively file a case to participate — you will not automatically be included as you would in some class actions.